2026 Q2 -tulosraportti
UUTTA
7 päivää sitten
‧48 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·44 min sittenHansa Biopharma (Q2 Review): SERB deal closed, December PDUFA supported by data Research Update 2026-07-23 10:40 Redeye maintains its positive view on Hansa Biopharma after a transformative second quarter. The company completed its out-licensing of Idefirix for 115 million euro in Europe to SERB Pharmaceuticals on July 1, with an upfront payment of 110 million euro financing the upcoming US launch without diluting shareholders. With pro forma cash of approximately 1.8 billion SEK supporting operations well into 2028, we see FDA's PDUFA date on December 19, 2026, as the single most important catalyst going forward. We reiterate our base case of 85 SEK.
·9 t sittenWhat I wrote 👇
Yes, nothing strange in this… but that you continue to write in the same way as you did before- ( before you reappeared) if you are now going to disappear completely from a forum, which you obviously did for a long time… k sa mdkr you should change the picture of the starling.. as far as I recall you were doing the same thing in Calliditas ? 🤔😎
·20 t sittenToday even the short seller PDT Partners LLC threw in the towel and gave up...only three short sellers left now.... 2218438 shares shorted 4.08% .....just to smile big.Only three public ones left now as you write - It will be interesting when Citadel, which has shorted for a long time, has to cover… could be a nice "short squeeze"…. Or what do you think?
·2 päivää sitten · MuokattuPublished just now on Avanza-/Placeraforum: "SEB analysis of Hansa Biopharma: Target Price will be even higher than 150 kr/share after the PDUFA decision 19 Dec 2026" Source (click or copy link and paste!) =>: https://forum.placera.se/inlagg/573e6e36-4a2e-468b-905e-c170a4e24875 / Regards Circus
- ·2 päivää sittenHas SEB previously succeeded in predicting Hansa's share price based on previous recommendations? Hardly…. STOCKHOLM (Direkt) SEB Equities raises the target price for Hansa Biopharma to 360 kronor from 175 kronor. The 'buy' recommendation is reiterated. https://proinvestor.com/boards/84975/HANSA-BIOPHARMA-SEB-H%C3%96JER-RIKTKURSEN-TILL-360-KRReply retrieved from Avanza-/Placera forum! Directly misleading post by Buy_And_hold (BAH). Hard to know what he really wants, other than to frantically try to "talk down" the price. . In his witch hunt to talk down the price, the user BAH has dug up a 7 (seven) year old outdated analysis by SEB from the archives - an analysis from the year 2020 ...(!) . But let's scrutinize this analysis in relation to today's analysis - almost 7 years later(!) . Firstly, so much water has flowed under the bridges in almost 7 years, that it becomes almost bizarre to bring up this analysis. . Secondly, to still make a small attempt, a few words are said here: . The target price of 360 kr/share in 2020 in SEB's old, outdated analysis, corresponds to a share price of approx. 157 kr / share today. . Consider that the number of shares in 2020 was approx. 44.5 million shares, compared to today approx. 102 million shares. The only thing that is relevant is to compare the market cap in 2020 with what this would correspond to translated to today's share capital! . My prognosis is that the share will easily surpass these 157 kr /share - measured by the 2020 share capital (number of shares): 360 kr/share. This is as soon as HighDes Imlifidase is de-risked by the FDA, which will happen at the PDUFA meeting on December 19, 2026. . A de-risking means that the discount rate for discounting is significantly lowered, with the consequence that the discounted value skyrockets, all else being equal. . Thus, when SEB biotech analyst Christopher Uhde updates his analysis (which he will do!) after the PDUFA decision on December 19, 2026, he will lower the discount rate. This is because de-risking has occurred, given a positive decision. . A lowering of the discount/calculation rate when preparing the DCF calculation results in the discounted price skyrocketing, from 150 kr /share, to perhaps 200 - 250 kr/share, depending on how much he chooses to lower the discount rate when calculating DCF, all else being equal! . Furthermore, a broad label, in itself, can mean that he chooses to significantly raise the sales estimates. This is because today's analysis only takes into account a narrow label: that only the most highly sensitized with CPRA > 99.99% will be treated with Imlifidase! . . Exciting times - to say the least! . . V.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
UUTTA
7 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·44 min sittenHansa Biopharma (Q2 Review): SERB deal closed, December PDUFA supported by data Research Update 2026-07-23 10:40 Redeye maintains its positive view on Hansa Biopharma after a transformative second quarter. The company completed its out-licensing of Idefirix for 115 million euro in Europe to SERB Pharmaceuticals on July 1, with an upfront payment of 110 million euro financing the upcoming US launch without diluting shareholders. With pro forma cash of approximately 1.8 billion SEK supporting operations well into 2028, we see FDA's PDUFA date on December 19, 2026, as the single most important catalyst going forward. We reiterate our base case of 85 SEK.
- ·9 t sittenWhat I wrote 👇Yes, nothing strange in this… but that you continue to write in the same way as you did before- ( before you reappeared) if you are now going to disappear completely from a forum, which you obviously did for a long time… k sa mdkr you should change the picture of the starling.. as far as I recall you were doing the same thing in Calliditas ? 🤔😎
- ·20 t sittenToday even the short seller PDT Partners LLC threw in the towel and gave up...only three short sellers left now.... 2218438 shares shorted 4.08% .....just to smile big.Only three public ones left now as you write - It will be interesting when Citadel, which has shorted for a long time, has to cover… could be a nice "short squeeze"…. Or what do you think?
- ·2 päivää sitten · MuokattuPublished just now on Avanza-/Placeraforum: "SEB analysis of Hansa Biopharma: Target Price will be even higher than 150 kr/share after the PDUFA decision 19 Dec 2026" Source (click or copy link and paste!) =>: https://forum.placera.se/inlagg/573e6e36-4a2e-468b-905e-c170a4e24875 / Regards Circus
- ·2 päivää sittenHas SEB previously succeeded in predicting Hansa's share price based on previous recommendations? Hardly…. STOCKHOLM (Direkt) SEB Equities raises the target price for Hansa Biopharma to 360 kronor from 175 kronor. The 'buy' recommendation is reiterated. https://proinvestor.com/boards/84975/HANSA-BIOPHARMA-SEB-H%C3%96JER-RIKTKURSEN-TILL-360-KRReply retrieved from Avanza-/Placera forum! Directly misleading post by Buy_And_hold (BAH). Hard to know what he really wants, other than to frantically try to "talk down" the price. . In his witch hunt to talk down the price, the user BAH has dug up a 7 (seven) year old outdated analysis by SEB from the archives - an analysis from the year 2020 ...(!) . But let's scrutinize this analysis in relation to today's analysis - almost 7 years later(!) . Firstly, so much water has flowed under the bridges in almost 7 years, that it becomes almost bizarre to bring up this analysis. . Secondly, to still make a small attempt, a few words are said here: . The target price of 360 kr/share in 2020 in SEB's old, outdated analysis, corresponds to a share price of approx. 157 kr / share today. . Consider that the number of shares in 2020 was approx. 44.5 million shares, compared to today approx. 102 million shares. The only thing that is relevant is to compare the market cap in 2020 with what this would correspond to translated to today's share capital! . My prognosis is that the share will easily surpass these 157 kr /share - measured by the 2020 share capital (number of shares): 360 kr/share. This is as soon as HighDes Imlifidase is de-risked by the FDA, which will happen at the PDUFA meeting on December 19, 2026. . A de-risking means that the discount rate for discounting is significantly lowered, with the consequence that the discounted value skyrockets, all else being equal. . Thus, when SEB biotech analyst Christopher Uhde updates his analysis (which he will do!) after the PDUFA decision on December 19, 2026, he will lower the discount rate. This is because de-risking has occurred, given a positive decision. . A lowering of the discount/calculation rate when preparing the DCF calculation results in the discounted price skyrocketing, from 150 kr /share, to perhaps 200 - 250 kr/share, depending on how much he chooses to lower the discount rate when calculating DCF, all else being equal! . Furthermore, a broad label, in itself, can mean that he chooses to significantly raise the sales estimates. This is because today's analysis only takes into account a narrow label: that only the most highly sensitized with CPRA > 99.99% will be treated with Imlifidase! . . Exciting times - to say the least! . . V.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
2026 Q2 -tulosraportti
UUTTA
7 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·44 min sittenHansa Biopharma (Q2 Review): SERB deal closed, December PDUFA supported by data Research Update 2026-07-23 10:40 Redeye maintains its positive view on Hansa Biopharma after a transformative second quarter. The company completed its out-licensing of Idefirix for 115 million euro in Europe to SERB Pharmaceuticals on July 1, with an upfront payment of 110 million euro financing the upcoming US launch without diluting shareholders. With pro forma cash of approximately 1.8 billion SEK supporting operations well into 2028, we see FDA's PDUFA date on December 19, 2026, as the single most important catalyst going forward. We reiterate our base case of 85 SEK.
- ·9 t sittenWhat I wrote 👇Yes, nothing strange in this… but that you continue to write in the same way as you did before- ( before you reappeared) if you are now going to disappear completely from a forum, which you obviously did for a long time… k sa mdkr you should change the picture of the starling.. as far as I recall you were doing the same thing in Calliditas ? 🤔😎
- ·20 t sittenToday even the short seller PDT Partners LLC threw in the towel and gave up...only three short sellers left now.... 2218438 shares shorted 4.08% .....just to smile big.Only three public ones left now as you write - It will be interesting when Citadel, which has shorted for a long time, has to cover… could be a nice "short squeeze"…. Or what do you think?
- ·2 päivää sitten · MuokattuPublished just now on Avanza-/Placeraforum: "SEB analysis of Hansa Biopharma: Target Price will be even higher than 150 kr/share after the PDUFA decision 19 Dec 2026" Source (click or copy link and paste!) =>: https://forum.placera.se/inlagg/573e6e36-4a2e-468b-905e-c170a4e24875 / Regards Circus
- ·2 päivää sittenHas SEB previously succeeded in predicting Hansa's share price based on previous recommendations? Hardly…. STOCKHOLM (Direkt) SEB Equities raises the target price for Hansa Biopharma to 360 kronor from 175 kronor. The 'buy' recommendation is reiterated. https://proinvestor.com/boards/84975/HANSA-BIOPHARMA-SEB-H%C3%96JER-RIKTKURSEN-TILL-360-KRReply retrieved from Avanza-/Placera forum! Directly misleading post by Buy_And_hold (BAH). Hard to know what he really wants, other than to frantically try to "talk down" the price. . In his witch hunt to talk down the price, the user BAH has dug up a 7 (seven) year old outdated analysis by SEB from the archives - an analysis from the year 2020 ...(!) . But let's scrutinize this analysis in relation to today's analysis - almost 7 years later(!) . Firstly, so much water has flowed under the bridges in almost 7 years, that it becomes almost bizarre to bring up this analysis. . Secondly, to still make a small attempt, a few words are said here: . The target price of 360 kr/share in 2020 in SEB's old, outdated analysis, corresponds to a share price of approx. 157 kr / share today. . Consider that the number of shares in 2020 was approx. 44.5 million shares, compared to today approx. 102 million shares. The only thing that is relevant is to compare the market cap in 2020 with what this would correspond to translated to today's share capital! . My prognosis is that the share will easily surpass these 157 kr /share - measured by the 2020 share capital (number of shares): 360 kr/share. This is as soon as HighDes Imlifidase is de-risked by the FDA, which will happen at the PDUFA meeting on December 19, 2026. . A de-risking means that the discount rate for discounting is significantly lowered, with the consequence that the discounted value skyrockets, all else being equal. . Thus, when SEB biotech analyst Christopher Uhde updates his analysis (which he will do!) after the PDUFA decision on December 19, 2026, he will lower the discount rate. This is because de-risking has occurred, given a positive decision. . A lowering of the discount/calculation rate when preparing the DCF calculation results in the discounted price skyrocketing, from 150 kr /share, to perhaps 200 - 250 kr/share, depending on how much he chooses to lower the discount rate when calculating DCF, all else being equal! . Furthermore, a broad label, in itself, can mean that he chooses to significantly raise the sales estimates. This is because today's analysis only takes into account a narrow label: that only the most highly sensitized with CPRA > 99.99% will be treated with Imlifidase! . . Exciting times - to say the least! . . V.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt